Compugen Ltd.(CGEN)Earnings, Financials & Key Ratios
CGEN•NASDAQ
$2.76
$247M mkt cap·Price updated May 6, 2026
AboutCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Show more
- Revenue$28M-16.7%
- EBITDA-$14M-15.1%
- Net Income-$14M+24.1%
- EPS (Diluted)-0.16+23.8%
- Gross Margin71.54%-23.9%
- EBITDA Margin-51.7%-38.2%
- Operating Margin-53.44%-37.6%
- Net Margin-51.07%+8.9%
- ROE-23.63%+9.8%
- ROIC-24.12%-50.4%
- Debt/Equity0.05+157.3%
- Interest Coverage-437.97-4.5%
CGEN Key Insights
Compugen Ltd. (CGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓FCF machine: 177.6% free cash flow margin
- ✓Momentum leader: RS Rating 92 (top 8%)
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CGEN Price & Volume
Compugen Ltd. (CGEN) stock price & volume — 10-year historical chart
Loading chart...
CGEN Growth Metrics
Compugen Ltd. (CGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.46%
5 Years-
3 Years66.84%
TTM-27.57%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM6.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM9.26%
Return on Capital
10 Years-39.4%
5 Years-26.22%
3 Years-22.06%
Last Year-15.68%
CGEN Recent Earnings
Compugen Ltd. (CGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (30%)
Q2 2026Latest
Mar 2, 2026EPS
$0.60
Est $0.07
+957.1%
Revenue
$67M
Est $2M
+3018.2%
Q4 2025
Nov 10, 2025EPS
$0.07
Est $0.09
+22.2%
Revenue
$2M
Est $14M
-86.8%
Q3 2025
Aug 6, 2025EPS
$0.08
Est $0.07
-14.3%
Revenue
$1M
Est $1M
-14.5%
Q2 2025
May 19, 2025EPS
$0.08
Est $0.06
-33.3%
Revenue
$2M
Est $4M
-38.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.60vs $0.07+957.1% | $67Mvs $2M+3018.2% |
| Q4 2025 | Nov 10, 2025 | $0.07vs $0.09+22.2% | $2Mvs $14M-86.8% |
| Q3 2025 | Aug 6, 2025 | $0.08vs $0.07-14.3% | $1Mvs $1M-14.5% |
| Q2 2025 | May 19, 2025 | $0.08vs $0.06-33.3% | $2Mvs $4M-38.3% |
Based on last 12 quarters of dataView full earnings history →
CGEN Peer Comparison
Compugen Ltd. (CGEN) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RXRX | 1.53B | 3.43 | -2.38 | 26.92% | -8.44% | -54.32% | 0.07 | |
 SDGR | 969.87M | 12.98 | -9.21 | 23.29% | -40.6% | -30.85% | 0.30 | |
 ABSI | 924.91M | 5.95 | -7.08 | -38.24% | -41.14% | -59.68% | 0.03 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 NKTX | 234.54M | 3.32 | -2.08 | -30.37% | 0.20 | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% |
Compare CGEN vs Peers
Compugen Ltd. (CGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGEN Income Statement
Compugen Ltd. (CGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 712K | 0 | 17.8M | 0 | 2M | 6M | 7.5M | 33.46M | 27.86M | 5.43M |
| Revenue Growth % | -92.33% | -100% | - | -100% | - | 200% | 25% | 346.12% | -16.72% | -27.57% |
| Cost of Goods Sold | 223K | 1.59M | 1.03M | 989K | 60K | 680K | 975K | 2M | 7.93M | 5.71M |
| COGS % of Revenue | 31.32% | - | 5.81% | - | 3% | 11.33% | 13% | 5.99% | 28.46% | - |
| Gross Profit | 489K▲ 0% | -1.59M▼ 425.8% | 16.77M▲ 1152.5% | -989K▼ 105.9% | 1.94M▲ 296.2% | 5.32M▲ 174.2% | 6.53M▲ 22.7% | 31.45M▲ 382.1% | 19.93M▼ 36.6% | -283K▲ 0% |
| Gross Margin % | 68.68% | - | 94.19% | - | 97% | 88.67% | 87% | 94.01% | 71.54% | -5.21% |
| Gross Profit Growth % | -93.6% | -425.77% | 1152.48% | -105.9% | 296.16% | 174.23% | 22.65% | 382.07% | -36.63% | - |
| Operating Expenses | 33.07M | 37.41M | 39.99M | 28.88M | 33.44M | 40.39M | 41.9M | 44.45M | 34.83M | 35.06M |
| OpEx % of Revenue | 4644.94% | - | 224.68% | - | 1671.8% | 673.23% | 558.65% | 132.84% | 124.98% | - |
| Selling, General & Admin | 8.52M | 8.82M | 9.68M | 9.06M | 10.68M | 11.7M | 11.25M | 9.97M | 10.02M | 9.51M |
| SG&A % of Revenue | 1197.05% | - | 54.35% | - | 533.8% | 195% | 150.01% | 29.81% | 35.94% | - |
| Research & Development | 24.55M | 28.58M | 30.32M | 19.82M | 22.76M | 28.69M | 30.65M | 34.47M | 24.81M | 25.55M |
| R&D % of Revenue | 3447.89% | - | 170.33% | - | 1138% | 478.23% | 408.64% | 103.03% | 89.04% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32.58M▲ 0% | -37.41M▼ 14.8% | -23.23M▲ 37.9% | -28.88M▼ 24.3% | -31.5M▼ 9.1% | -35.07M▼ 11.4% | -35.37M▼ 0.9% | -12.99M▲ 63.3% | -14.89M▼ 14.6% | -35.34M▲ 0% |
| Operating Margin % | -4576.26% | - | -130.49% | - | -1574.8% | -584.57% | -471.65% | -38.83% | -53.44% | -650.68% |
| Operating Income Growth % | -55.77% | -14.8% | 37.9% | -24.33% | -9.06% | -11.36% | -0.86% | 63.27% | -14.62% | - |
| EBITDA | -31.1M | -35.81M | -21.83M | -27.89M | -30.78M | -34.61M | -34.89M | -12.52M | -14.4M | -33.32M |
| EBITDA Margin % | -4367.84% | - | -122.66% | - | -1539.05% | -576.88% | -465.23% | -37.41% | -51.7% | -613.42% |
| EBITDA Growth % | -56.97% | -15.15% | 39.03% | -27.74% | -10.37% | -12.45% | -0.81% | 64.13% | -15.09% | 2.46% |
| D&A (Non-Cash Add-back) | 1.48M | 1.59M | 1.39M | 989K | 715K | 461K | 482K | 476K | 486K | 0 |
| EBIT | -32.58M | -37.05M | -23.23M | -28.03M | -29.66M | -35.07M | -33.61M | -12.99M | -14.89M | -33.32M |
| Net Interest Income | 705K | 15K | 620K | 903K | 1.72M | 869K | 1.41M | 3.21M | 5.2M | 3.09M |
| Interest Income | 728K | 523K | 643K | 935K | 1.76M | 894K | 1.44M | 3.24M | 5.24M | 3.09M |
| Interest Expense | 705K | 508K | 620K | 32K | 42K | 25K | 27K | 31K | 34K | 0 |
| Other Income/Expense | 1.1M | 339K | 628K | 820K | 1.8M | 871K | 1.74M | 3.21M | 5.18M | 4.04M |
| Pretax Income | -31.49M▲ 0% | -37.07M▼ 17.7% | -22.6M▲ 39.0% | -28.06M▼ 24.2% | -29.7M▼ 5.8% | -34.2M▼ 15.2% | -33.64M▲ 1.7% | -9.78M▲ 70.9% | -9.71M▲ 0.8% | -31.3M▲ 0% |
| Pretax Margin % | -4422.19% | - | -126.96% | - | -1484.9% | -570.05% | -448.48% | -29.24% | -34.84% | -576.22% |
| Income Tax | 20K | 0 | 0 | -722K | 0 | 0 | 58K | 8.97M | 4.52M | 54K |
| Effective Tax Rate % | -0.06% | 0% | 0% | 2.57% | 0% | 0% | -0.17% | -91.68% | -46.58% | -0.17% |
| Net Income | -31.51M▲ 0% | -37.07M▼ 17.6% | -22.6M▲ 39.0% | -27.34M▼ 21.0% | -29.7M▼ 8.6% | -34.2M▼ 15.2% | -33.69M▲ 1.5% | -18.75M▲ 44.3% | -14.23M▲ 24.1% | -31.35M▲ 0% |
| Net Margin % | -4425% | - | -126.96% | - | -1484.9% | -570.05% | -449.25% | -56.05% | -51.07% | -577.21% |
| Net Income Growth % | -56.26% | -17.65% | 39.03% | -20.97% | -8.64% | -15.17% | 1.49% | 44.34% | 24.12% | 6.28% |
| Net Income (Continuing) | -31.51M | -37.07M | -22.6M | -27.34M | -29.7M | -34.2M | -33.69M | -18.75M | -14.23M | -31.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.62▲ 0% | -0.72▼ 16.1% | -0.41▲ 43.1% | -0.43▼ 4.9% | -0.37▲ 14.0% | -0.41▼ 10.8% | -0.39▲ 4.9% | -0.21▲ 46.2% | -0.16▲ 23.8% | -0.34▲ 0% |
| EPS Growth % | -55% | -16.13% | 43.06% | -4.88% | 13.95% | -10.81% | 4.88% | 46.15% | 23.81% | 9.26% |
| EPS (Basic) | -0.62 | -0.72 | -0.41 | -0.43 | -0.37 | -0.41 | -0.39 | -0.21 | -0.16 | - |
| Diluted Shares Outstanding | 50.86M | 51.18M | 55.28M | 63.64M | 79.59M | 84.2M | 86.56M | 87.63M | 89.53M | 93.54M |
| Basic Shares Outstanding | 50.86M | 51.18M | 55.28M | 63.64M | 79.59M | 84.2M | 86.56M | 87.63M | 89.53M | 93.54M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CGEN Balance Sheet
Compugen Ltd. (CGEN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 62.68M | 31.18M | 46.58M | 45M | 129.09M | 123.22M | 86.13M | 114.58M | 106M | 88.92M |
| Cash & Short-Term Investments | 61.53M | 30.44M | 45.67M | 43.88M | 123.77M | 117.05M | 83.35M | 50.69M | 103.25M | 86.09M |
| Cash Only | 61.53M | 30.44M | 45.67M | 9.84M | 7.14M | 7.8M | 11.06M | 13.89M | 18.23M | 7.46M |
| Short-Term Investments | 0 | 0 | 0 | 34.04M | 116.62M | 109.25M | 72.29M | 36.8M | 85.03M | 78.63M |
| Accounts Receivable | 82K | 51K | 167K | 341K | 2M | 188K | 317K | 61.32M | 269K | 2.83M |
| Days Sales Outstanding | 42.04 | - | 3.42 | - | 365 | 11.44 | 15.43 | 668.91 | 3.52 | 210.12 |
| Inventory | -2.06M | -1.74M | -1.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 721K | 713K | 362K | 365K | 0 | 0 |
| Total Non-Current Assets | 8.46M | 7.57M | 6.6M | 8.76M | 9.23M | 8.94M | 8.05M | 6.75M | 9M | 8.93M |
| Property, Plant & Equipment | 5.96M | 4.65M | 3.37M | 5.58M | 4.48M | 3.9M | 3.36M | 2.54M | 3.69M | 3.38M |
| Fixed Asset Turnover | 0.12x | - | 5.28x | - | 0.45x | 1.54x | 2.23x | 13.15x | 7.54x | 1.64x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 371K |
| Other Non-Current Assets | 2.49M | 2.92M | 3.23M | 3.18M | 4.74M | 5.04M | 4.69M | 4.21M | 5.3M | 20.06M |
| Total Assets | 71.14M▲ 0% | 38.75M▼ 45.5% | 53.18M▲ 37.3% | 53.76M▲ 1.1% | 138.32M▲ 157.3% | 132.16M▼ 4.4% | 94.18M▼ 28.7% | 121.33M▲ 28.8% | 115M▼ 5.2% | 97.84M▲ 0% |
| Asset Turnover | 0.01x | - | 0.33x | - | 0.01x | 0.05x | 0.08x | 0.28x | 0.24x | 0.06x |
| Asset Growth % | -28.36% | -45.53% | 37.25% | 1.1% | 157.27% | -4.45% | -28.74% | 28.84% | -5.22% | -31.96% |
| Total Current Liabilities | 4.74M | 6.19M | 9.99M | 6.82M | 10.52M | 17.1M | 11.92M | 26.27M | 20.16M | 20.28M |
| Accounts Payable | 1.27M | 3.44M | 2.95M | 1.09M | 1.41M | 4.62M | 1.77M | 3.5M | 1.84M | 0 |
| Days Payables Outstanding | 2.09K | 789.34 | 1.04K | 401.54 | 8.6K | 2.48K | 663.74 | 637.84 | 84.6 | 28.6 |
| Short-Term Debt | 0 | 0 | 0 | 600K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 312K | 1.09M | 774K | 0 | 0 | 0 | 11.15M | 9.63M | 30.85M |
| Other Current Liabilities | 2.07M | 1.08M | 3.45M | 1.71M | 668K | 6.93M | 3.14M | 3.13M | 3.07M | 9.12M |
| Current Ratio | 13.22x | 5.03x | 4.66x | 6.60x | 12.27x | 7.21x | 7.23x | 4.36x | 5.26x | 5.26x |
| Quick Ratio | 13.66x | 5.31x | 4.80x | 6.60x | 12.27x | 7.21x | 7.23x | 4.36x | 5.26x | 5.26x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 181.52 |
| Total Non-Current Liabilities | 2.88M | 3.25M | 5.95M | 8.62M | 8.01M | 8.37M | 4.58M | 29.51M | 39.92M | 33.74M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 2.98M | 2.53M | 1.98M | 1.31M | 719K | 2.46M | 8.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.88M | 3.25M | 2.94M | 2.95M | 5.48M | 6.39M | 3.27M | 3.4M | 3.41M | 13.72M |
| Total Liabilities | 7.62M | 9.45M | 15.94M | 15.44M | 18.53M | 25.47M | 16.5M | 55.77M | 60.08M | 54.02M |
| Total Debt | 0 | 0 | 0 | 3.58M | 3.17M | 2.75M | 1.93M | 1.35M | 2.91M | 2.95M |
| Net Debt | -61.53M | -30.44M | -45.67M | -6.26M | -3.98M | -5.05M | -9.13M | -12.54M | -15.32M | -4.51M |
| Debt / Equity | - | - | - | 0.09x | 0.03x | 0.03x | 0.02x | 0.02x | 0.05x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.09x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.14x |
| Interest Coverage | -46.22x | -73.63x | -37.46x | -902.47x | -749.90x | -1402.96x | -1310.15x | -419.10x | -437.97x | - |
| Total Equity | 63.52M▲ 0% | 29.3M▼ 53.9% | 37.24M▲ 27.1% | 38.32M▲ 2.9% | 119.78M▲ 212.6% | 106.69M▼ 10.9% | 77.68M▼ 27.2% | 65.56M▼ 15.6% | 54.91M▼ 16.2% | 43.83M▲ 0% |
| Equity Growth % | -29.34% | -53.88% | 27.12% | 2.89% | 212.58% | -10.93% | -27.19% | -15.6% | -16.24% | -33.32% |
| Book Value per Share | 1.25 | 0.57 | 0.67 | 0.60 | 1.50 | 1.27 | 0.90 | 0.75 | 0.61 | 0.47 |
| Total Shareholders' Equity | 63.52M | 29.3M | 37.24M | 38.32M | 119.78M | 106.69M | 77.68M | 65.56M | 54.91M | 43.83M |
| Common Stock | 140K | 140K | 164K | 187K | 231K | 239K | 240K | 247K | 248K | 0 |
| Retained Earnings | -270.96M | -308.24M | -330.84M | -358.18M | -387.88M | -422.08M | -455.77M | -474.53M | -488.76M | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 7K | 17K | 0 | 0 | 0 | 0 | 0 | 2K | 11K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGEN Cash Flow Statement
Compugen Ltd. (CGEN) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -19.82M | -30.66M | -13.29M | -27.89M | -28.32M | -23.22M | -33.92M | -35.89M | 49.6M | 49.6M |
| Operating CF Margin % | -2783.57% | - | -74.67% | - | -1416% | -386.98% | -452.29% | -107.25% | 178.02% | - |
| Operating CF Growth % | 22.6% | -54.69% | 56.65% | -109.83% | -1.55% | 18.01% | -46.1% | -5.79% | 238.23% | 0% |
| Net Income | -31.51M | -37.07M | -22.6M | -27.34M | -29.7M | -34.2M | -33.69M | -18.75M | -14.23M | -31.35M |
| Depreciation & Amortization | 1.48M | 1.59M | 1.39M | 989K | 715K | 461K | 482K | 476K | 486K | 0 |
| Stock-Based Compensation | 3.08M | 2.63M | 2.17M | 2.41M | 2.77M | 4.28M | 4.33M | 3.55M | 3.02M | 0 |
| Deferred Taxes | -383K | 0 | 52K | -135K | -12K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 101K | -33K | 46K | -22K | 184K | -573K | 515K | -452K | -1.72M | 31.35M |
| Working Capital Changes | 7.4M | 2.21M | 5.65M | -3.79M | -2.28M | 6.82M | -5.55M | -20.71M | 62.05M | 0 |
| Change in Receivables | 7.8M | 422K | -179K | -142K | -2M | 2M | 3.04M | -61.11M | 59.93M | 0 |
| Change in Inventory | 518K | 247K | -954K | 3.5M | -3.82M | -3.37M | 0 | 0 | 0 | 0 |
| Change in Payables | -605K | 1.56M | 2.69M | -3.5M | 3.82M | 3.37M | -1.6M | 3.51M | -4.41M | 0 |
| Cash from Investing | 16.29M | 46.27M | -35.16M | 5.33M | -82.17M | 6.62M | 37.06M | 35.51M | -46.25M | 0 |
| Capital Expenditures | -2.6M | -385K | -158K | -155K | -166K | -292K | -487K | -172K | -118K | 0 |
| CapEx % of Revenue | 365.03% | - | 0.89% | - | 8.3% | 4.87% | 6.49% | 0.51% | 0.42% | - |
| Acquisitions | 0 | -46.66M | 2K | 382K | 44K | 3K | 2K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 84K | 46.66M | 2K | 0 | 0 | 0 | 0 | 0 | -329K | 0 |
| Cash from Financing | 2.46M | 201K | 28.4M | 25.93M | 108.46M | 16.84M | 353K | 3.08M | 554K | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 353K | 1000K | 544K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.46M | 201K | 685K | 3.17M | 34.32M | 1.88M | 0 | 0 | 10K | 0 |
| Net Change in Cash | -1.07M▲ 0% | 15.82M▲ 1581.1% | -20.05M▼ 226.8% | 3.37M▲ 116.8% | -2.03M▼ 160.2% | 704K▲ 134.7% | 2.91M▲ 312.9% | 2.83M▼ 2.5% | 3.97M▲ 40.2% | 30.1M▲ 0% |
| Free Cash Flow | -22.42M▲ 0% | -31.04M▼ 38.5% | -13.45M▲ 56.7% | -28.04M▼ 108.5% | -28.49M▼ 1.6% | -23.04M▲ 19.1% | -34.99M▼ 51.9% | -36.06M▼ 3.0% | 49.49M▲ 237.2% | 0▲ 0% |
| FCF Margin % | -3148.6% | - | -75.56% | - | -1424.3% | -384.03% | -466.57% | -107.77% | 177.6% | - |
| FCF Growth % | 21.96% | -38.47% | 56.68% | -108.51% | -1.58% | 19.11% | -51.87% | -3.04% | 237.24% | 100% |
| FCF per Share | -0.44 | -0.61 | -0.24 | -0.44 | -0.36 | -0.27 | -0.40 | -0.41 | 0.55 | 0.55 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.83x | 0.59x | 1.02x | 0.95x | 0.68x | 1.01x | 1.91x | -3.49x | -0.00x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGEN Key Ratios
Compugen Ltd. (CGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -41.07% | -79.87% | -67.93% | -72.35% | -37.57% | -30.2% | -36.55% | -26.19% | -23.63% | -71.54% |
| Return on Invested Capital (ROIC) | -466.89% | -6593.13% | - | -183.34% | -31.95% | -24.19% | -31.18% | -16.03% | -24.12% | -24.12% |
| Gross Margin | 68.68% | - | 94.19% | - | 97% | 88.67% | 87% | 94.01% | 71.54% | -5.21% |
| Net Margin | -4425% | - | -126.96% | - | -1484.9% | -570.05% | -449.25% | -56.05% | -51.07% | -577.21% |
| Debt / Equity | - | - | - | 0.09x | 0.03x | 0.03x | 0.02x | 0.02x | 0.05x | 0.05x |
| Interest Coverage | -46.22x | -73.63x | -37.46x | -902.47x | -749.90x | -1402.96x | -1310.15x | -419.10x | -437.97x | - |
| FCF Conversion | 0.63x | 0.83x | 0.59x | 1.02x | 0.95x | 0.68x | 1.01x | 1.91x | -3.49x | -0.00x |
| Revenue Growth | -92.33% | -100% | - | -100% | - | 200% | 25% | 346.12% | -16.72% | -27.57% |
CGEN Frequently Asked Questions
Compugen Ltd. (CGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Compugen Ltd. (CGEN) reported $5.4M in revenue for fiscal year 2024. This represents a 68% increase from $3.2M in 1999.
Compugen Ltd. (CGEN) saw revenue decline by 16.7% over the past year.
Compugen Ltd. (CGEN) reported a net loss of $31.4M for fiscal year 2024.
Dividend & Returns
Compugen Ltd. (CGEN) has a return on equity (ROE) of -23.6%. Negative ROE indicates the company is unprofitable.
Compugen Ltd. (CGEN) generated $49.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CGEN
Compugen Ltd. (CGEN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates